Tvardi publishes new preclinical ulcerative colitis data for STAT3 inhibitor TTI-101 in Int J Mol Sci
TVRD•Tvardi Therapeutics published preclinical ulcerative colitis data showing its oral STAT3 inhibitor TTI-101 concentrated in the colon and reduced disease biology linked to inflammation and abnormal tissue growth. The findings support advancing next-generation inhibitor TTI-109 toward ulcerative colitis development.
1. Preclinical findings published
Tvardi Therapeutics disclosed newly published preclinical ulcerative colitis data for TTI-101. The study found that the oral drug concentrated in the colon and broadly reduced disease biology linked to inflammation and abnormal tissue growth; the findings strengthen the rationale to advance next-generation STAT3 inhibitor TTI-109 toward ulcerative colitis development.
